HUMANIN TRIFLUOROACETATE cas: 330936-69-1

CAS NO: 330936-69-1
CBNumber: CB6205843
name: HUMANIN TRIFLUOROACETATE
MF: C119H204N34O32S2
MW: 2687.27
CAS: 330936-69-1
Description Review
Description
An In-depth Look at HUMANIN TRIFLUOROACETATE (CAS: 330936-69-1)

Understanding HUMANIN TRIFLUOROACETATE: Its Chemical Properties, Health Benefits, and Potential Effects.
Introduction:
HUMANIN TRIFLUOROACETATE is a significant compound that has garnered attention in the scientific community for its potential health benefits and mechanisms of action. This article delves deep into the intricacies of this compound, shedding light on its chemical properties, benefits, and potential side effects.
Top Ten Keywords from Google and Synonyms:
1. Neuroprotective peptide
2. Amyloid-beta
3. Hormone-like peptide
4. Apoptosis in cancer cells
5. Mitochondrial Peptide
6. Humanin
7. CAS 330936-69-1
8. Humanin Trifluoroacetate Powder
9. Peptide Human Hn Trifluoroacetate
10. Chemical Properties
Synonyms:
- Humanin
- Formyl humanin
- Protein Humanin (human)
Similar Competitive Products:
While HUMANIN TRIFLUOROACETATE stands out for its unique properties, there are other peptides and compounds in the market that exhibit neuroprotective effects. However, the exact competitive products would require further research.
Health Benefits of this Product:
HUMANIN TRIFLUOROACETATE is known for its neuroprotective properties. It has shown potential in suppressing neuronal cell death, which is induced by several familial Alzheimer's disease genes and by amyloid β-protein.
Potential Effects:
The compound has been associated with inducing apoptosis in cancer cells, making it a potential candidate for cancer research.
Product Mechanism:
The exact mechanism of HUMANIN TRIFLUOROACETATE is still under research. However, its neuroprotective effects against Alzheimer's disease genes suggest its role in neural pathways and interactions with amyloid proteins.
Safety:
While HUMANIN TRIFLUOROACETATE has shown promise in laboratory settings, its safety profile in humans is still under investigation. It's essential to approach its use with caution until more comprehensive studies are conducted.
Side Effects:
As with any compound, there's a potential for side effects. However, specific side effects related to HUMANIN TRIFLUOROACETATE are yet to be documented comprehensively.
Dosing Information:
The appropriate dosage of HUMANIN TRIFLUOROACETATE varies based on its application and the individual's health status. It's crucial to consult with a healthcare professional before considering its use.
Contraindication:
There might be specific contraindications associated with HUMANIN TRIFLUOROACETATE, especially for individuals with certain health conditions or those on specific medications. A thorough medical consultation is recommended.
Conclusion:
HUMANIN TRIFLUOROACETATE is a fascinating compound with potential health benefits, especially in neuroprotection. While its exact mechanisms and full range of applications are still under research, the compound holds promise for future therapeutic applications. As with any substance, it's essential to approach its use with an informed perspective, considering both its potential benefits and risks.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code